Literature DB >> 11174007

Cardiac hypertrophy in the Prague-hypertensive rat is associated with enhanced JNK2 but not ERK tissue activity.

V Vogel1, D Bokemeyer, J Heller, H J Kramer.   

Abstract

Mitogen-activated protein (MAP) kinases are important intracellular mediators for proliferation and hypertrophy and therefore may also regulate cardiomyoblast growth in hypertensive heart disease. Thus, the aim of the present study was to examine the activities of MAP kinases, namely extracellular signal-regulated kinase (ERK)1,2, c-Jun NH2-terminal kinases (JNK)1,2 and p38 MAP kinase, in myocardial tissue of 12-week-old Prague normotensive (PNR) and hypertensive rats (PHR), a model of genetic hypertension with marked cardiac hypertrophy. Systolic blood pressure was 121 +/- 5 in PNR and 208 +/- 15 mm Hg in PHR (p < 0.01). Total heart weight was 247 +/- 4 in PNR vs. 316 +/- 4 mg/100 g body weight in PHR (p < 0.01). Left and right ventricular weights were 121 +/- 5 and 53 +/- 3 in PNR vs. 168 +/- 4 (p < 0.01) and 57 +/- 2 mg/100 g body weight (n.s.) in PHR. Using anti-ERK2 Western blot analysis as well as immunocomplex ERK activity assay, we found no activation of ERK2 in left or right ventricular tissue of PHR and PNR. Similary, p38 MAP kinase phosphorylation and activity were not detectable. In contrast, Western blot analysis using antiphospho-JNK antibodies revealed in myocardial tissue of right and left ventricles significantly greater phosphorylation of JNK2 in PHR than in PNR. This finding was confirmed by immunocomplex JNK activity assay using ATF-2 as substrate, which demonstrated a significant increase in JNK activity in the left ventricle of PHR as compared to PNR (6.4 +/- 1.5 vs. 2.5 +/- 0.5 OD; each n = 5; p < 0.05). In conclusion, cardiac JNK2 seems to be regulated differently from ERK2 in this rat model. In PHR, as compared to PNR, we found enhanced activity of JNK2 in the left and right ventricles suggesting that JNK2 is involved in hypertensive cardiac disease. The rise in JNK in both ventricles may result indirectly from humoral stimuli, e.g., endothelin-1 and/or angiotensin II, and may contribute to ventricular hypertrophy in this model of spontaneous hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174007     DOI: 10.1159/000054206

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  4 in total

1.  Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.

Authors:  Susumu Matsuda; Seiji Umemoto; Koichi Yoshimura; Shinichi Itoh; Tomoaki Murata; Tohru Fukai; Masunori Matsuzaki
Journal:  J Atheroscler Thromb       Date:  2015-03-05       Impact factor: 4.928

2.  Antihypertensive activity of a new c-Jun N-terminal kinase inhibitor in spontaneously hypertensive rats.

Authors:  Mark B Plotnikov; Oleg I Aliev; Aleksandr Y Shamanaev; Anastasia V Sidekhmenova; Anna M Anishchenko; Tatiana I Fomina; Victoria S Rydchenko; Andrei I Khlebnikov; Yana J Anfinogenova; Igor A Schepetkin; Dmitriy N Atochin
Journal:  Hypertens Res       Date:  2020-05-07       Impact factor: 3.872

3.  Catecholamine-induced cardiac hypertrophy in rats is associated with the activation of p70 kinase and c-Jun NH(2)-terminal kinase 2.

Authors:  Monika Leicht; Nora Greipel; Beate Raßler; Heinz-Gerd Zimmer
Journal:  Exp Clin Cardiol       Date:  2002

4.  JNK2 regulates vascular remodeling in pulmonary hypertension.

Authors:  Mita Das; W Michael Zawada; James West; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2018-05-02       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.